Aktis Oncology, Inc. (AKTS)
| Market Cap | 1.04B |
| Revenue (ttm) | 8.28M +1,394.0% |
| Net Income | -67.07M |
| EPS | -5.25 |
| Shares Out | 55.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138,618 |
| Open | 19.87 |
| Previous Close | 19.89 |
| Day's Range | 18.70 - 20.23 |
| 52-Week Range | 14.72 - 29.16 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 32.65 (+73.03%) |
| Earnings Date | May 11, 2026 |
About AKTS
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company’s lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform which is in ongoing Phase 1b clinical trial for the treatment of Nectin-4 expressing solid tumors, including locally advanced or metastatic urothelial cancer, breast cancer, NSCLC, colorectal cancer and cervical cancer; and [225Ac]Ac-AKY-2519 to deliver 225A... [Read more]
Financial Performance
In 2025, Aktis Oncology's revenue was $6.50 million, an increase of 336.92% compared to the previous year's $1.49 million. Losses were -$63.73 million, 44.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for AKTS stock is "Strong Buy." The 12-month stock price target is $32.65, which is an increase of 73.03% from the latest price.
News
Aktis Oncology Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a proprietary radiopharmaceutical platform with two lead clinical programs targeting Nectin-4 and B7-H3, both showing promising early data and broad multi-indication potential. Robust supply chain and manufacturing infrastructure support aggressive clinical expansion, with key data readouts and new candidates expected in 2027 and early next year.
Aktis Oncology price target raised to $35 from $33 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology (AKTS) to $35 from $33 and keeps a Buy rating on the shares after the company presented…
Aktis Oncology to Present at the Jefferies Global Healthcare Conference
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmace...
Aktis Oncology Transcript: Status update
AKY-2519, a B7-H3-targeting radiopharmaceutical, demonstrated robust tumor uptake, high tumor-to-normal tissue dose ratios, and favorable safety in early studies. Experts highlighted its potential to address unmet needs in prostate and other solid tumors, with clinical trials underway in multiple indications.
Aktis Oncology Slides: Status update
Aktis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 27, 2026.
Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
BOSTON, May 21, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop...
Aktis Oncology Transcript: Bank of America Global Healthcare Conference 2026
The company is advancing miniprotein radioconjugate therapies targeting Nectin-4 and B7-H3, supported by a robust discovery platform and strong financial position. Key clinical updates are expected in 2027, with ongoing collaborations and manufacturing investments to accelerate development and patient access.
Aktis Oncology reports Q1 revenue $3.23M, consensus $1.85M
Cash, cash equivalents and marketable securities were $538.5M as of March 31, compared to $226.8M as of December 31, 2025. “We continue to build momentum toward delivering a new class…
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop...
Aktis Oncology Earnings release: Q1 2026
Aktis Oncology released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Aktis Oncology Quarterly report: Q1 2026
Aktis Oncology has published its Q1 2026 quarterly earnings report on May 11, 2026.
Aktis Oncology to Present at the BofA Securities Health Care Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmace...
Aktis Oncology Transcript: Study update
AKY-2519, a B7-H3-targeted radioconjugate, has entered phase I-B trials for mCRPC, with a parallel basket trial in other solid tumors planned for late 2026. Imaging and dosimetry data will be presented at ASCO, and preliminary clinical data are expected in 2027.
Aktis Oncology Press release: Study update
Aktis Oncology issued a press release on May 5, 2026, disclosing material business information to investors.
Aktis Oncology Slides: Study update
Aktis Oncology has posted slides in relation to its latest quarterly earnings report, which was published on May 5, 2026.
Aktis Oncology initiates clinical trial of AKY-25191
Aktis Oncology (AKTS) announced the initiation of a Phase 1b clinical trial of AKY-25191 in patients with metastatic castration-resistant prostate cancer. The mCRPC-dedicated Phase 1b trial is part of...
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (Aktis or the Company), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiop...
Aktis Oncology initiated with an Outperform at William Blair
William Blair initiated coverage of Aktis Oncology (AKTS) with an Outperform rating. The company is positioned to become a radiopharmaceuticals leader by using miniproteins to address novel targets wi...
Aktis Oncology appoints Gormley as independent director of Board of Directors
Aktis Oncology (AKTS) announced the appointment of Glenn Gormley, MD, PhD, as an independent director to its Board of Directors and co-chair of the Company’s newly established Science and Technology…
Aktis Oncology Appoints Industry Research and Development Veteran Glenn Gormley, MD, PhD to its Board of Directors
BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharma...
Aktis Oncology price target raised to $33 from $30 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Aktis Oncology (AKTS) to $33 from $30 and keeps a Buy rating on the shares following the Q4 report.
Aktis Oncology announces FDA clearance of AKY-25191 trial
Aktis Oncology (AKTS) announced the FDA cleared the investigational new drug applications for the company to proceed to a Phase 1b clinical trial with AKY-25191. AKY-2519 is a miniprotein radioconjuga...
Aktis Oncology Announces FDA Clearance of Investigational New Drug Applications for AKY-2519 and Provides Business Updates and Full Year 2025 Financial Results
BOSTON, March 30, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharma...
Aktis Oncology Earnings release: Q4 2025
Aktis Oncology released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
Aktis Oncology Annual report: Q4 2025
Aktis Oncology has published its Q4 2025 annual report on March 30, 2026.